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Summary The c-myc oncogene has been implicated in the processes of normal cell proliferation and
differentiation. Elevated levels of c-myc mRNA and its gene product (p62C.mYc), have been detected in a
variety of solid tumours and cultured cell lines. Its precise role in normal cell function and in neoplastic
transformation and progression has yet to be elucidated. We have used a monoclonal antibody, raised by
peptide immunisation, to determine the distribution by immunoperoxidase staining of the c-myc oncogene
product in archival specimens of colonic polyps and carcinomas. Samples from 42 patients with colon
carcinoma, 24 with benign polyps and 15 normal colon biopsies were examined. Normal colon revealed
maximum staining in the mid-zone of the crypts, corresponding to the zone of differentiation and maturation.
The staining was predominantly cytoplasmic. Adenomatous polyps revealed the most intense pattern of
staining in areas of dysplastic change. Colonic tumours showed a wide range of staining. Well differentiated
tumours contained more cytoplasmic p62c-mYc than poorly differentiated tumours. These findings suggest that
the c-myc oncogene product may play an important role in the evolution ofcolonic neoplasia.
The study of retroviruses has altered our
perspectives on the molecular biology of normal
and malignant cell proliferation. The discovery of
proto-oncogenes, the cellular homologues of viral
genes which have transforming ability, has been the
basis for this change (Cooper & Lane, 1984).
Twenty-five proto-oncogenes have now been
identified, molecularly cloned and their sequence
determined (Hamlyn & Sikora, 1983). A variety of
mechanisms, including gene amplification,
translocation and mutation have been identified as
abnormal activators of several oncogenes (Burgess,
1985).
Much work has been carried out to identify the
functional products of these genes. The c-sis gene
has been shown to code for a subunit of platelet
derived growth factor (PDGF) (Waterfield et al.,
1983) and the c-erb B gene encodes for the
intracellular component of the epidermal growth
factor (EGF) receptor- suggesting important roles
for these oncogene products in growth control
(Downward et al., 1984). Abnormalities in the c-
myc gene and its expression have been found in a
wide variety of tumours. The level of c-myc mRNA
increases rapidly when a cell is stimulated to divide
and both the mRNA and its gene product, the
62,000 dalton protein (p62c-mYc), both have a short
half life of 20 minutes (Rabbitts et al., 1985).
Stimulation of fibroblasts by PDGF and EGF
results in cell-cycle initiation leading to a
subsequent rise in c-myc RNA levels (Kelly et al.,
1983). Increased expression of c-myc has been seen
in several cell lines when stimulated to proliferate,
in regenerating normal liver (Goyette et al., 1983),
and during normal embryogenesis (Muller et al.,
1982). p62C-MYC is associated with the nuclear frac-
tion of proliferating cells (Eisenman et al., 1985).
It also has been found to have DNA binding
activity, though Evan and Hancock (1985) have
shown that in intact nuclei treated with DNAse
at low salt concentration, p62c-mYc is still present. It
is probable therefore that the binding of p62c-mYc to
DNA is not the only means by which the gene
product is associated with the nucleus. These data
would suggest that p62c-mYc may have a role in cell
cycle control.
It is the breakdown of the normal molecular
control mechanisms that result in the neoplastic
phenotype. The contribution of abnormal levels of
p62c-mYc to the development and maintenance of
the malignant state is not currently understood.
We have recently developed a set of monoclonal
antibodies to p62c-mYc by peptide fragment
immunisation (Evan et al., 1985). One such anti-
body, Myc 1-6E10, recognises p62c-mYc in paraffin
wax embedded histological samples (Sikora- et al.,
1985). The subcellular localisation of p62c-mYc
as detected by this antibody is predominantly
cytoplasmic reflecting changes in cellular p62c-mYc
distribution due to fixation. Indeed freshly
harvested human tumour cell lines stained by
immunofluorescence without fixation show clear
nuclear fluorescence.
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Colorectal carcinoma is a major cause of death
from malignant disease. There is good evidence that
many large bowel cancers are preceded by a series
of adenomatous changes (Mato et al., 1975). Here
we report a retrospective immunohistological ana-
lysis of colonic specimens using the anti p62c-mYc
antibody to obtain an insight into the role of this
protein in the adenoma-carcinoma sequence.
Patients and methods
Monoclonal antibody
The methods employed in peptide synthesis,
inoculation of mice and the screening procedures
used for deriving Myc-l 6E10 have been fully
described elsewhere (Evan et al., 1985). The MCA
was raised to a synthetic peptide consisting of
residues 171-188 of the human p62c-mYc sequence.
Hybridoma cells were grown in the ascitic fluid
of female BALB/c mice. The antibody was purified
by octanoic acid precipitation followed by
ammonium sulphate concentration. The purified
antibody was adjusted to a concentration of
2mgml-' in PBS with 0.001% sodium azide,
aliquoted and stored at -20°C. A mouse immuno-
globulin of the same subclass (IgG1k) was obtained
from the ascitic fluid of the mouse myeloma line X-
63 (Kohler & Milstein, 1975). This was similarly
purified and also adjusted to a concentration of
2mgml1 and was employed as an inappropriate
antibody control. Anti-CEA (Dakopat) was
employed as a positive control monoclonal
antibody.
Immunohistology
Routinely processed formal saline fixed paraffin
blocks containing specimens obtained at surgery
were extracted from the archives of the Department
of Pathology, Addenbrooke's Hospital. Forty-two
patients with carcinoma, 24 with benign polyps,
and 15 normal colon biopsies were studied. The
specimens were sectioned on a bench microtome.
Sections (5pm) were placed on standard microscope
slides which had been previously coated in a 0.5%
gelatin solution containing 250mg chrome alum
and 30mg sodium azide per 100ml and air dried at
room temperature overnight.
An avidin-biotin staining technique was
employed (Vectorstain, ABC Kit, Vector Labs).
Briefly, the sections were dewaxed and rehydrated
through alochol. Endogenous peroxidase activity
was blocked by incubating for 15min in 5%
hydrogen peroxide in PBS (pH7.2). The sections
were washed for 20min in PBS. Excess serum was
blotted off and the sections incubated in a moisture
chamber for 60min at room temperature with
100p1 Myc-1 6E10, diluted 1/500 in PBS, 1% BSA
and 0.25% Triton X-100. Sections were washed in
PBS and then incubated with a biotinylated rabbit
anti-mouse immunoglobulin. After washing,
sections were incubated with the ABC reagent. The
substrate was developed by a final incubation with
a diaminobenzidine solution (20ml PBS, 10mg
DAB (Sigma), 20pl H202 100vol). The sections
were washed in running tap water, counterstained
with Mayers haemalum for 60s, dehydrated,
cleared, and mounted.
Results
Specificity controls
All carcinoma specimens studied revealed con-
siderable staining using the Myc-I 6E10 antibody.
An irrelevant mouse monoclonal immunoglobulin
(X-63) of the same Ig subclass revealed no binding.
Anti-CEA monoclonal (Dakopats) was used as a
positive control. Staining by Myc-I 6E10 but not
anti-CEA antibody was blocked by the addition of
1 ug of the peptide used as the immunogen added
to 100M1 of antibody prior to its addition to the
section indicating specific antigen recognition
(Table I).
Table I Specificity controls
Staining intensity
Normal Polyp Carcinoma
Myc-I 6E10 + ++ +++
Myc peptide blocked
Myc-l 6E10 - - -
Anti-CEA + + + + +
Myc-peptide blocked
Anti-cea + + + + +
X63 IgGk - - -
Normal colon Fifteen samples of normal colon
were examined. The presence of p62c-myc in a
normal colon biopsy is shown in Figure 1. Maximal
staining was present in the transition zone between
the actively dividing cells of the crypt base and the
mature surface epithelium.
Polyps Samples from 24 patients were studied.
Thirteen had villous adenomas and 11 pure
adenomas. Ten of these polyps were isolated lesions
from patients who had polyps removed
endoscopically. The remaining polyps were from
patients with co-existing carcinomas. In all polyps
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the crypt cells as well as in the maturing zone
(Figures 2 and 3). The staining was mainly
cytoplasmic. In some of the larger polyps with
dysplastic change the staining was particularly
intense and extended to the mucosal surface.
Carcinomas Forty-two patients with carcinomas
were investigated. Twenty-nine were classed as
moderately to well differentiated and 13 poorly
differentiated. The patients were further divided
into two groups depending on whether they were
alive or dead at five years. The carcinomas showed
varying degrees of cytoplasmic staining (Figures 4
and 5). There was no correlation with depth of
invasion nor was there any correlation with those
patients alive at five years or those dead within five
years from their disease. The poorly differentiated
tumours showed the least staining. (Summary Table
II).
Discussion
Several oncogenes have been implicated in the
development of tumours in patients. Abnormalities
in expression of the c-ras gene family have been
identified in bladder, colon and lung tumours
(Slamon et al., 1984). Abnormal c-myc gene
expression has been extensively studied in Burkitt's
lymphoma (Melchers et al., 1984). Here
chromosomal translocations bring the c-myc gene in
close proximity to the immunoglobulin heavy or
light chain loci. Other methods of c-myc activation
have been discovered in vitro such as the loss of
transcriptional repression through deletion of the
untranslated 5' exon (Rabbitts et al., 1984) and the
abnormal use of promoters in malignant cells
(Hamlyn & Rabbitts, 1983). These genetic changes
result in an elevated level of either normal or
abnormal gene product which subverts the normal
growth control pattern resulting in the transformed
phenotype.
The c-myc gene has been shown to have a role in
cell division and differentiation. The analysis of
mRNA from human placentae reveals that the peak
transcriptional activity occurs between four and five
weeks after conception (Pfeifer-Ohlsson et al.,
1984). In cells growing in tissue culture the
progression from quiescence to active DNA
synthesis, the driving of cells from Go into the G1
phase of the cycle, may well be a function of
p62c mYc. Several systems have implicated the role of
this protein in differentiation (Sikora et al., 1985)
although the precise molecular mechanisms
involved are unclear.
Staining with Myc-I 6E10 was predominantly
cytoplasmic despite the known nuclear location of
p62c-mYc from immunochemical studies. The fixation
process used for clinical specimens causes the
redistribution of p62c-mYc. Fresh human tumour cell
lines studied by immunofluorescence show a
predominantly nuclear localisation for this protein.
This becomes cytoplasmic after fixation (Stewart et
al., unpublished). Furthermore, it has been
previously demonstrated that p62c-mYc is extracted
from nuclei by mild salt concentrations (below
200mM) without affecting gross nuclear structure
or causing extraction of major chromatin
components. The fractionation of nuclei in the
presence of isotonic sodium chloride (144mM)
results in virtually quantitative extraction of p62c-myc
from nuclei when assayed by immunochemical
means (Evan & Hancock, 1985). Despite the lack of
information provided on the subcellular localisation
Table II Summary of immunohistory results with anti p62c-mYc
antibody
Number Staining
Specimen studied intensity Distribution
Normal Maturation zone
colon 15 + only
Polyps Crypts and
adenomatous 11 + + maturation zone
villous 13 + + + + Crypts, maturation
zone and dyplastic
areas
Carcinomas
Moderate to well
differentiated 29 + +.+ + All cells
Poorly
differentiated 13 + + All cells4 J. STEWART et al.
./
Figure 1 A section of normal colon stained with
Myc 1 6E10 showing a crypt of Leiberkuhn cut
longitudinally. Staining is most abundant in the
maturation zone ( x 400). Figure 2 Adenomatous polyp
( x400). Figure 3 Villous polyp showing intense
staining at crypt base ( x 1000). Figure 4 Well differen-
tiated colorectal carcinoma showing abundant p62cmYc
in cells (x 1000). Figure 5 Poorly differentiated
colorectal carcinoma showing some p62c-YC (x 1000).
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of p62c-mYc a quantitative estimate can be obtained
of total cellular content using immunohistological
techniques.
Normal colonic epithelial cells have a rapid
turnover rate of 4 to 6 days depending on their
type and site. Within the crypts of Lieberkuhn there
is considerable variation in the proliferative rate as
studied by the uptake of tritiated thymidine
(Deschner et al., 1966). This suggests that the cells
of the colon are susceptible to different controls or
have a range of sensitivities to the molecular
triggers for cell cycle entry. Our study suggests that
p62c-mYc may be involved in the maturation process
for it is present in greatest abundance in the
transitional zone of the normal colon (Figure 6).
This has also been observed in the normal colonic
mucosa of mice using an MCA to p62c-myc (R.
Buick, personal communication). As a result of
prolonged exposure to dietary carcinogens and their
metabolites genetic changes occur in certain cells
resulting in the abnormal accumulation of p62c-myc
and subsequent dysplastic change. The lesions most
commonly associated with malignant change are
those with a villous architecture and which express
the greatest quantity of p62c-mYc. Areas of dysplastic
change also contain abundant p62c-mYc.
There is evidence that other oncogenes are active
in colonic neoplasia, indicating a sequential
activation or interplay which would add strength to
the argument of multi-stage carcinogenesis (Thor et
al., 1984). Gallick et al. (1985) demonstrated
elevated levels of p2lras in 9 of 17 primary colonic
lesions (8 were graded Dukes stage B or C),
however, 4 of 5 tumours classified as having distant
metastasis did not show elevated levels. In all the
metastases, p2lIas levels were low. They concluded
that the elevation of p2lIas may be an early
phenomenon in colon cancer and that tumour
progression led to an autonomous population of
cells in which other growth factors replaced the role
of p2lIas. Similar results have been obtained by
NORMAL ADENOMA CARCINOMA
3H-THY
Mature zone l1
Maturation _I U-I' Proliferative il
zone
C-MYC
Mature zone
Maturation II
Proliferative m|
zone
Figure 6 Diagrammatic representation of tritiated
thymidine uptake and p62cmYc distribution in normal
colon, polyp and carcinoma. Dark shading indicates
areas of considerable uptake or staining; unshaded
areas - no uptake or staining, with stippled areas
being in-between (cf. Deschner et al., 1966).
examining c-myc mRNA transcripts in polyps and
neoplasms (Spandidos et al., 1984).
Elevated p62c-myc expression may therefore either
represent the 'driving mechanism' for the increased
rate of cell proliferation or it may be a consequence
of the activation of other oncogenes. We are
currently investigating the distribution and quantity
of several oncogene transcripts and gene products
in colonic lesions. By using monoclonal antibodies
raised against such proteins we can begin to dissect
their precise role in the development of human
cancer and harness them as tools for diagnosis,
prognosis and future therapy.
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